Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update

Rhea-AI Summary

Ampio Pharmaceuticals (AMPE) announced a conference call to discuss its financial results for Q1 2021 on May 5, 2021, at 4:30 PM EDT. The company focuses on immunology-based therapies for inflammatory conditions, notably its lead drug, Ampion, which has patent protection through 2035 and may gain 12-year FDA market exclusivity post-approval. The call will cover financial metrics and strategic updates, available via the company website for future reference.

Positive

• Lead drug Ampion backed by extensive patent portfolio until 2035.
• Potential 12-year FDA market exclusivity upon approval.

Negative

• None.

ENGLEWOOD, Colo., April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended March 31, 2021 and provide a corporate business update on Wednesday, May 5, 2021 at 4:30pm EDT/ 2:30pm MT.

Conference Call & Webcast:
Wednesday, May 5, 2021, 4:30pm EDT / 2:30pm MT
Domestic:	888-506-0062 - Conference ID# 268913
International:	973-528-0011 - Conference ID# 268913
Webcast Link:	https://www.webcaster4.com/Webcast/Page/2569/40836

The conference call will also be available from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

Forward Looking Statements

Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter  into partnering arrangements,  clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts 
Investor Relations 
Joe Hassett 
joeh@gregoryfca.com 
484-686-6600

Media Contact 
Katie Kennedy  
katiek@gregoryfca.com 
610-731-1045

View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-report-fiscal-2021-first-quarter-financial-results-and-provide-corporate-business-update-301273698.html

SOURCE Ampio Pharmaceuticals, Inc.

FAQ

When is the Ampio Pharmaceuticals conference call for Q1 2021 results?

The conference call is scheduled for May 5, 2021, at 4:30 PM EDT.

What is Ampio Pharmaceuticals' lead drug?

Ampio's lead drug is Ampion, aimed at treating prevalent inflammatory conditions.

What potential exclusivity does Ampion have?

Ampion may receive 12-year market exclusivity from the FDA upon approval.

Where can I find more information about Ampio Pharmaceuticals?

More information can be found on their official website at www.ampiopharma.com.

What key financial updates will be discussed on the conference call?

The conference call will cover financial results for the quarter ended March 31, 2021, along with corporate business updates.